SAR439459
Total Payments
$991,482
Transactions
127
Doctors
9
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $966,218 | 104 | 9 |
| 2018 | $25,263 | 23 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $991,323 | 122 | 100.0% |
| Food and Beverage | $158.20 | 5 | 0.0% |
Payments by Type
Research
$991,323
122 transactions
General
$158.20
5 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1/1b First-in-Human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Administered Intravenously as Mono | SANOFI US SERVICES INC. | $517,775 | 0 |
| A Phase 1/1b First-in-Human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With REGN2810 in Adult Patients With Advanced Solid Tumors | SANOFI US SERVICES INC. | $461,856 | 0 |
| A Phase 1/2 study for the safety, efficacy, pharmacokinetic and pharmacodynamics evaluation of SAR439859, administered orally as monotherapy, then in combination with palbociclib in postmenopausal wom | SANOFI-AVENTIS U.S. LLC | $11,692 | 4 |
Top Doctors Receiving Payments for SAR439459
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Atlanta, GA | $979,631 | 102 |
| , M.D., PH.D | Medical Oncology | New York, NY | $2,923 | 5 |
| , M.D. PH.D | Diagnostic Radiology | Los Angeles, CA | $2,923 | 5 |
| Hannah Linden | Medical Oncology | Seattle, WA | $2,923 | 5 |
| , MD | Medical Oncology | Boston, MA | $2,923 | 5 |
| , M.D | Hematology & Oncology | New York, NY | $31.64 | 1 |
| , M.D | Medical Oncology | Boston, MA | $31.64 | 1 |
| , MD | Emergency Medicine | Cambridge, MA | $31.64 | 1 |
| , M.D | Occupational Medicine | Orlando, FL | $31.64 | 1 |
| , MD | Medical Oncology | Westwood, KS | $31.64 | 1 |
Ad
Manufacturing Companies
- SANOFI US SERVICES INC. $979,631
- SANOFI-AVENTIS U.S. LLC $11,850
Product Information
- Type Drug
- Total Payments $991,482
- Total Doctors 9
- Transactions 127
About SAR439459
SAR439459 is a drug associated with $991,482 in payments to 9 healthcare providers, recorded across 127 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI US SERVICES INC..
Payment data is available from 2018 to 2019. In 2019, $966,218 was paid across 104 transactions to 9 doctors.
The most common payment nature for SAR439459 is "Unspecified" ($991,323, 100.0% of total).
SAR439459 is associated with 3 research studies, including "A Phase 1/1b First-in-Human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Administered Intravenously as Mono" ($517,775).